COSM-loaded biphase calcium phosphate bone cement and preparation method thereof

By adding chitooligosaccharide to biphasic calcium phosphate bone cement, the COSM biphasic calcium phosphate bone cement was prepared, which solved the problem of insufficient biocompatibility and mechanical properties of bone cement materials, and achieved efficient bone regeneration and blood vessels. Generates, providing a safe and effective alternative material for biological bone.

CN118873752APending Publication Date: 2024-11-01GUANGZHOU RAINHOME PHARM&TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410603359.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-15
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

Existing bone cement materials have problems of insufficient biocompatibility and mechanical properties in bone regeneration and repair, especially in the absence of effective solutions in drug loading and promoting angiogenesis.

Method used

By adjusting the preparation conditions of biphasic calcium phosphate, chitooligosaccharide (COSM) was added to prepare COSM-loaded biphasic calcium phosphate bone cement, the biphasic tricalcium phosphate containing α-phase and β-phase were synthesized by high-temperature solid-phase reaction method, and the biphasic tricalcium phosphate containing α-phase and β-phase was combined with The aqueous solution of chitin oligosaccharide is mixed to form a bone cement material with good vascularization effect.

Benefits of technology

It achieves high compressive strength, good biocompatibility and promotes angiogenesis of bone cement materials. It has significant effect on drug release in vitro, conforms to the human bone healing rules, and provides a safe and effective alternative material for biological bones.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention relates to the field of calcium phosphate bone cement, in particular to COSM-loaded biphase calcium phosphate bone cement and a preparation method thereof. According to the COSM-loaded biphasic calcium phosphate bone cement provided by the invention, chitosan oligosaccharide COSM with the average molecular weight of less than or equal to 3000Da is loaded in the biphasic calcium phosphate bone cement, and in-vitro experiments show that the COSM-loaded biphasic calcium phosphate bone cement has a good blood vessel forming effect. According to the preparation method of the COSM-loaded biphase calcium phosphate bone cement provided by the invention, COSM-BCP in in-vitro drug release of the prepared calcium phosphate bone cement is in a mode of first burst release and then slow release, and the COSM-BCP can be stably and continuously released.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of calcium phosphate bone cement, and in particular to a COSM-loaded biphasic calcium phosphate bone cement and a preparation method thereof. Background Art

[0002] Bones are one of the most important organs in the human body. They provide support for the body, help with movement, and protect the internal organs of the human body. Unfortunately, there are many cases of bone defects every year due to traffic accidents, sports, and large machine work, and bone and related diseases account for nearly 50% of people over 50 years old. In the United States, about 500,000 patients undergo bone transplant surgery each year, and this number will double worldwide. Therefore, it is urgent to develop safe and non-toxic biological bone substitute materials for treatment, which is also an important task at present.

[0003] Tricalcium phosphate (TCP, Ca3(PO4)2), one of the most studied calcium phosphates along with hydroxyapatite, is a calcium phosphate with a calcium / phosphorus ratio of 1.5 and is divided into α-phase and β-phase. α-TCP has a crystal structure with a monoclinic space group, and β-TCP has a crystal structure with a rhombohedral space group. α-TCP can be formed at temperatures of 1125°C or higher, and β-TCP can be formed at temperatures of 900–1100°C. β-TCP has a more stable structure and a higher biodegradation rate than α-TCP. Therefore, β-TCP is generally used for bone regeneration. β-TCP is not as stable as HAP, but it degrades faster and has a higher solubility. In addition, it has a high absorption rate and is widely used to increase biocompatibility. β-TCP promotes the proliferation of bone precursor cells such as osteoblasts and bone marrow stromal cells. These properties are due to the excellent biomineralization and cell adhesion of the nanoporous structure of β-TCP. The properties of β-TCP have been actively studied for bone regeneration purposes, and β-TCP has been widely used in bone cement and bone replacement.

[0004] To exploit the properties of both TCP and HAP, biphasic materials have been developed. Biphasic or multiphasic calcium phosphates exist in an unseparated form because each component is uniformly and intimately mixed at the submicron level. Biphasic forms of calcium phosphate were first prepared in 1986 as a mixture of hydroxyapatite and β-tricalcium phosphate. These biphasic calcium phosphates typically combine two more incompatible calcium phosphates, such as the more stable hydroxyapatite and the more soluble tricalcium phosphate, and they are mainly evaluated in terms of bioactivity, bioresorbability, and osteoinductivity. Biphasic calcium phosphates have been used and studied as bone grafts, bone substitutes, and dental materials. A mixture of hydroxyapatite and β-tricalcium phosphate has been actively used to stimulate osteogenic differentiation of mesenchymal stem cells, increase cell adhesion, attach growth factors, and enhance mechanical properties. Ramay et al. constructed a biodegradable porous nanocomposite scaffold containing a β-TCP matrix and HAP nanofibers. The β-TCP / HAP scaffold was prepared by a gel-polymer approach and is expected to provide enhanced mechanical properties in load-bearing bone tissue engineering. The biphasic calcium phosphate scaffold was found to have a microporous structure that affects cell growth and angiogenesis.

[0005] Chitosan oligosaccharides (COS) are degradation products of chitosan. They have higher water solubility and lower viscosity, and are easily absorbed by organisms, which makes them have broad and unique application prospects in the fields of medicine, food, agriculture, daily chemical industry, and bio-health care. Calcium phosphate bone cement has good biocompatibility and injectability. When used, it only needs to mix its solid phase powder with the solidifying liquid in a certain proportion, and it can solidify itself to reach a certain strength. It has excellent plasticity and can be shaped according to the shape of the bone defect. It has strong adaptability to the shape of the bone defect and is suitable for the needs of clinical operations. The weakly crystalline hydroxyapatite generated by the hydration reaction in its solid body is similar to the inorganic components of human bone tissue. It is a bone repair material with broad application prospects. Summary of the invention

[0006] The present invention adjusts and optimizes the preparation conditions of biphasic calcium phosphate, adds COSM (MW≤3000 Da) to the optimally formulated biphasic calcium phosphate bone cement particles, and characterizes the physical and chemical properties thereof. The safety evaluation of COSM-BCP bone cement particles and the preliminary pharmacodynamic evaluation of in vitro angiogenesis are studied, providing an experimental basis for the development of drug-loaded biological bone substitute materials.

[0007] To achieve the purpose of the present invention, the present invention first provides a COSM-loaded biphasic calcium phosphate bone cement, wherein the COSM-loaded biphasic calcium phosphate bone cement has a good angiogenic effect.

[0008] The present invention also provides a method for preparing a COSM-loaded biphasic calcium phosphate bone cement, which can prepare the COSM-loaded biphasic calcium phosphate bone cement.

[0009] The present invention provides a COSM-loaded biphasic calcium phosphate bone cement, comprising: Solid phase composition: biphasic tricalcium phosphate containing α phase and β phase; Liquid phase component: aqueous solution containing chitosan oligosaccharide.

[0010] The present invention uses a high temperature solid phase reaction method to prepare the biphasic tricalcium phosphate, wherein CaCO3 and CaHPO4 are fully mixed in proportion and converted into α-TCP and β-TCP under high temperature conditions, and the chemical reaction equation is as follows:

[0011] In some embodiments, the method for preparing the biphasic tricalcium phosphate (ie, BCP) powder comprises the following steps: (1) Drying → Mixing → Drying: Place appropriate amounts of CaCO3 powder and CaHPO4 powder in an oven to dry, weigh calcium carbonate and anhydrous calcium hydrogen phosphate powder in a molar ratio of 1:2, pour into a ball mill, and mix well. Then add an appropriate amount of anhydrous ethanol and mill using a planetary ball mill. Pour the slurry into a tray, dry it naturally, and after the ethanol evaporates, place it in an oven to continue drying to obtain a mixed powder; (2) Primary calcination: Pour the mixed powder obtained in the above (1) into a crucible with a powder thickness not exceeding 1.5 cm, place it in a muffle furnace at room temperature, heat it at a certain heating rate until 900°C, start the calcination timer, keep it at this temperature for a certain period of time, and cool it down with the furnace; or directly proceed to step (3); the cooled powder is passed through a 100-mesh sieve and sieved for later use; (3) Second high-temperature calcination: The powder obtained in (2) is heated to 1200-1400°C and calcined. After keeping the temperature for a certain period of time, it is immediately taken out and rapidly cooled to room temperature in air to obtain block crystals. (4) Ball milling → drying → sieving: Pour the block crystals obtained in (3) into a mortar and grind them into fine particles. Then pour them into a ball mill, add an appropriate amount of ethanol, and ball mill. After the ethanol evaporates, put them in an oven to dry. The obtained powder is sieved through a 325-mesh sieve to obtain a biphasic tricalcium phosphate powder with a median particle size of about 50 μm.

[0012] In other embodiments, the preparation method of the biphasic tricalcium phosphate is as follows: CaCO3 and CaHPO4 are mixed according to the method of step (1); in step (2), they are first calcined at 900°C for a certain time; then, in step (3), the temperature is directly raised to 1200-1400°C for a certain time; then, the mixture is immediately taken out and rapidly cooled to room temperature by air to obtain block crystals; and then, the biphasic tricalcium phosphate is obtained according to the operation of step (4).

[0013] In some preferred embodiments, the calcination temperature in step (3) is 1300° C. and the calcination time is 2 h; and the molar ratio of the α-phase to the β-phase tricalcium phosphate is about 1:1.

[0014] In the present invention, the chitosan oligosaccharide is COSM with an average molecular weight of ≤3000 Da.

[0015] In the present invention, the mass concentration of chitosan oligosaccharide in the liquid phase component in water is 0-10wt%; in some embodiments, COSM is added to make it into a liquid phase containing 0 wt%, 1 wt%, 2 wt%, 5 wt%, and 10 wt% COSM.

[0016] In some embodiments, the liquid phase components also include citric acid and disodium hydrogen phosphate.

[0017] In some embodiments, in the liquid phase component, the citric acid is citric acid monohydrate, and its mass concentration in water is 1-3%, preferably 2.09wt%; the mass concentration of disodium hydrogen phosphate in water is 3-6%, preferably 5.0wt%.

[0018] A method for preparing a COSM-loaded biphasic calcium phosphate bone cement, characterized in that the solid phase component and the liquid phase component are uniformly mixed and formed in a mold according to a certain mass ratio.

[0019] In a preferred embodiment, the mass ratio of the solid phase component to the liquid phase component is 1:(0.5-0.6).

[0020] In some embodiments, the solid phase component of BCP bone cement is a biphasic tricalcium phosphate mixed with α-TCP and β-TCP in different ratios.

[0021] In some embodiments, the liquid phase component is prepared by weighing 4.18 g of citric acid monohydrate and 10 g of disodium hydrogen phosphate, adding them into a beaker, adding water to dissolve them, and then adding COSM to make a liquid phase containing 0 wt%, 1 wt%, 2 wt%, 5 wt%, and 10 wt% COSM, and adjusting the volume to 200 mL.

[0022] In some embodiments, a certain amount of solid phase powder is weighed with a weighing balance, and the solidified liquid is weighed according to the mass ratio of the solid phase component to the liquid phase component, that is, the solid-liquid ratio is 1:0.5. The two are placed in a mortar and stirred evenly with a glass rod, and quickly filled into a stainless steel cylindrical hole mold with a diameter of ф6 mm × 12 mm for compaction. A T-shaped punch is used to apply a little pressure to press and form the bone cement particles. After the bone cement particles are formed, they are ejected. During this period, the curing time can be measured, and the prepared bone cement particles are placed in a constant temperature box at 37°C and 100% humidity for curing. After 3 days, the compressive strength, phase analysis and other tests can be performed.

[0023] Beneficial effects of the present invention: (1) The present invention provides a COSM-loaded biphasic calcium phosphate bone cement. First, the ratio of α-TCP / β-TCP biphasic tricalcium phosphate is determined by XRD, and the optimal formula is obtained by analysis. The curing time is moderate and the compressive strength is high. The MIP results show that the porosity of BCP bone cement particles is 52.09%, the average pore size is 76.59 nm, the total pore volume is 0.3938 mL / g, and the total pore area is 20.568 m2 / g. In addition, the anti-disintegration rate is good, the in vitro degradation rate is in line with the law of human bone healing, and the mass retention rate after 37 days is 95.54±0.38%.

[0024] (2) The present invention provides a COSM-loaded biphasic calcium phosphate bone cement, wherein COSM is dissolved in a solidifying liquid to prepare COSM solidifying liquids of different concentrations, and COSM-BCP bone cement particles are prepared. The surface morphology of COSM-BCP bone cements with different contents was observed by SEM. The higher the COSM concentration, the more obvious the fish scale structure; the solidification time and compressive strength also showed a positive correlation. The MIP results showed that the porosity of 5 wt% COSM-BCP was slightly reduced to 50.18%, the average pore size was 49.16 nm, the total pore volume was 0.3761 mL / g, and the total pore area was 30.597 m2 / g. The porosity reached the level of normal human bones (50~90%). In vitro drug release showed that it was first released suddenly and then slowly released, and it could be released stably and continuously in the drug-carrying system.

[0025] (3) The present invention provides a COSM-loaded biphasic calcium phosphate bone cement, and the biocompatibility study was conducted through a cytotoxicity experiment. The results showed that the COSM-BCP extract at each concentration had no obvious toxicity to MC3T3-E1s and HUVECs, the cell morphology was normal, and it played a positive role in proliferation. In the HUVEC cell scratch study and tubule formation experiment, it was found that COSM-BCP had good cell affinity and promoted the migration and spreading of HUVECs. In addition, COSM-BCP has an excellent angiogenic effect. In addition, the RT-PCR results showed that the COSM-BCP extract upregulated the expression of angiogenesis-related genes in HUVECs. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 XRD patterns of tricalcium phosphate powder synthesized with different intermediate holding times Figure 2 XRD patterns of tricalcium phosphate powders synthesized at different calcination reaction temperatures Figure 3 XRD patterns of tricalcium phosphate powder synthesized at different calcination reaction times Figure 4 SEM images of bone cement loaded with 0 wt%, 1 wt%, 2 wt%, 5 wt%, and 10 wt% COSM Figure 5 Figure 2. (A) Cumulative mercury intrusion versus pore size; (B) Incremental mercury intrusion versus pore size; (C) Total pore area versus pore size; and (D) Logarithmic differential mercury intrusion versus pore size of COSM-loaded biphasic calcium phosphate cement. Figure 6 Figure 1. (A) Cumulative mercury intrusion versus pore size; (B) Incremental mercury intrusion versus pore size; (C) Total pore area versus pore size; and (D) Logarithmic differential mercury intrusion versus pore size of biphasic calcium phosphate cement. Figure 7 Comparison of curing time of bone cement loaded with different contents of COSM (n=3) Figure 8 Comparison of compressive strength of bone cement loaded with different contents of COSM (n=5) Fig. 9 Macroscopic appearance of biphasic calcium phosphate cement particles after oscillation in PBS for 1 min, 3 min, 7 min, 11 min, and 15 min Fig.10 Anti-disintegration rate of biphasic calcium phosphate cement particles after oscillation in PBS for 15 min Fig.11 Changes in mass retention of biphasic calcium phosphate cement particles after immersion in PBS for 37 days Fig.12 In vitro drug release curves of COSM-BCP loaded with different contents of COSM Fig.13 Observation pictures of MC3T3-E1 cells after 1 day and 3 days of culture (×100) Fig.14 The proliferation rate of MC3T3-E1 cells in the presence of extracts of different concentrations at 1 d (A) and 3 d (B) was determined by CCK-8 assay (n=6, mean±SD) (Note: compared with the Control group, *p<0.05, ***p<0.001, ****p<0.0001).

[0027] Fig.15 Observation pictures of HUVEC cells after 1 day and 3 days of culture (×100) Fig.16 The proliferation rates of HUVECs in the presence of extracts of different concentrations at 1 d (A) and 3 d (B) were determined by CCK-8 assay (n=6, mean±SD) (Note: compared with the Control group, *p<0.05, ***p<0.001, ****p<0.0001).

[0028] Fig.17 Effects of different concentrations of extracts on the migration ability of HUVEC at different time points Fig.18 Quantitative analysis of the scratch area of ​​HUVEC at different time points under different concentrations of extracts (n=3, mean±SD) Fig.19 Effects of different concentrations of extracts on the tube-forming ability of HUVEC at different time points Fig. 20 Quantitative analysis of the tube-forming ability of HUVEC at different time points under different concentrations of extracts (n=5, mean±SD) Fig.21 Quantification of scratch area of ​​HUVEC cells and expression of ANG1 (A), bFGF (B), CXCR4 (C), PDGFB (D), VEGFA (E), and VEGFB (F) genes (n=3, mean±SD). DETAILED DESCRIPTION

[0029] The present invention provides a COSM-loaded biphasic calcium phosphate bone cement, comprising: Solid phase composition: biphasic tricalcium phosphate containing α phase and β phase; Liquid phase component: aqueous solution containing chitosan oligosaccharide.

[0030] The present invention uses a high temperature solid phase reaction method to prepare the biphasic tricalcium phosphate, wherein CaCO3 and CaHPO4 are fully mixed in proportion and converted into α-TCP and β-TCP under high temperature conditions, and the chemical reaction equation is as follows:

[0031] In some embodiments, the method for preparing the biphasic tricalcium phosphate (BCP) powder comprises the following steps: (1) Drying → Mixing → Drying: Place appropriate amounts of CaCO3 powder and CaHPO4 powder in an oven and dry them. Weigh calcium carbonate and anhydrous calcium hydrogen phosphate powder in a molar ratio of 1:2, pour them into a ball mill and mix them. Then add an appropriate amount of anhydrous ethanol and mill them using a planetary ball mill. Pour the slurry into a tray, dry it naturally, and place it in an oven to continue drying after the ethanol evaporates to obtain a mixed powder.

[0032] In some preferred embodiments, appropriate amounts of CaCO3 powder and CaHPO4 powder are placed in an oven at 70°C for 4 h, and calcium carbonate and anhydrous calcium hydrogen phosphate powder are weighed at a molar ratio of 1:2, poured into a ball mill, and mixed. Then, an appropriate amount of anhydrous ethanol is added, and the mixture is ball milled at 400 rpm / min for 2 h using a planetary ball mill. The slurry is poured into a tray, dried naturally, and after the ethanol is evaporated, it is placed in an oven at 70°C for another 4 h.

[0033] (2) Primary calcination: Pour the mixed powder obtained in (1) above into a crucible with a powder thickness not exceeding 1.5 cm. Place it in a muffle furnace at room temperature and heat it at a certain heating rate until 900°C, then start the calcination timer. Keep the temperature for a certain period of time and cool it down with the furnace. After cooling, the powder is ball-milled and sieved for later use.

[0034] In some embodiments, the mixed powder obtained in (1) above is poured into a crucible with a powder thickness not exceeding 1.5 cm, placed in a muffle furnace at room temperature, and heated at a heating rate of 5 °C / min until 900 °C, and the calcination time is started, and the temperature is kept for 1 h, 2 h, and 3 h respectively, and the temperature is lowered with the furnace. The cooled powder is ball milled for 2 h, passed through a 100-mesh sieve, and the prepared BCP powder is set aside. Samples are taken for phase analysis of the synthetic product, and the appropriate insulation time is selected according to the purity of the synthesized β-TCP.

[0035] Phase XRD detection: MiniFlex 600 X-ray diffractometer (XRD, Rigaku, Japan) was used to analyze the phase composition of the BCP powder. Test conditions: Cu-Kα radiation, wavelength 0.15418 nm (15418 A), voltage 40 KV, current 30 mA, scanning speed 0.2 ° / min, scanning range 20°~40°, and measurement angle error less than ±0.01°.

[0036] According to the above method, the XRD results are analyzed as follows: A method for producing a biphasic calcium phosphate containing two different (α- and β-) crystals of tricalcium phosphate is known to obtain a biphasic calcium phosphate, including α- and β-modifications of tricalcium phosphate, from β-TCP powder by sintering the preformed powder at a temperature above the β-TCP to α-TCP phase transition temperature. Generally, the synthetic route forms β-TCP before the desired α phase. This study aims to study the β- and α-mixed powders of tricalcium phosphate prepared from β-TCP powder, so it is necessary to explore the effect of calcination time at 900 °C on the purity of the formed β-TCP.

[0037] Table 1 Ratio of content of different crystalline tricalcium phosphate synthesized at different intermediate holding times No. Intermediate holding time (h) α-TCP content (%) β-TCP content (%) A 1 0 100 B 2 0 100 C 3 0 100

[0038] CaCO3 and CaHPO4 were converted into β-TCP precursors by high-temperature solid-phase reaction, and the temperature was kept at 900 °C for 1 h, 2 h, and 3 h, respectively, in order to study the effect of the intermediate holding time on the synthesis of β-TCP. Figure 1 It can be seen that the β-TCP synthesized by the three holding times has strong diffraction peaks at 2θ=31.026°, 34.371°, 27.769°, 52.944°, 25.802°, 32.448°, 46.968°, 17.004° and other positions. Compared with the β-TCP standard card PDF#09-0169, the position and intensity of the diffraction peaks are consistent, and there are no other impurity peaks. The content was determined and analyzed by Jade 6.5, and the composition ratio of the phase in the calcined product at different intermediate holding times was obtained. As shown in Table 1, the β-TCP content can reach 100%. In summary, when the temperature reaches 900 ℃, calcination for 1 h can be completely converted into β-TCP, and no other products appear when the calcination time is extended, and the precursor is relatively stable. In order to save energy and calcination time efficiency, a 1 h intermediate holding time can generally be selected for subsequent calcination treatment.

[0039] In other embodiments, the mixed powder obtained in the above (1) is placed in a crucible and placed in a muffle furnace, and heated to 900° C. at a heating rate of 5° C. / min and kept at this temperature for 1 h, 2 h, and 3 h, respectively, and then directly proceeding to step (3).

[0040] (3) Second high-temperature calcination: The powder obtained in (2) is heated to 1200-1400°C for calcination again. After keeping the temperature for a certain period of time, it is immediately taken out and rapidly cooled to room temperature in air to obtain block crystals.

[0041] In some embodiments, the powder obtained in (2) is poured into a crucible again and placed in a muffle furnace, and the temperature is increased again at a heating rate of 5 °C / min, and calcined at 1200 °C, 1300 °C, and 1400 °C for 4 h, respectively, and then immediately removed from the air and rapidly cooled to room temperature to obtain block crystals. The step (4) operation is performed to perform phase analysis and compressive strength measurement on the synthesized product, and the calcination reaction temperature with better performance is selected according to the performance of the synthesized biphasic calcium phosphate.

[0042] After reaching the calcination temperature, the product is taken out immediately after being kept at the temperature for a certain period of time, and then rapidly cooled to room temperature by air to obtain block crystals. Using the same XRD experimental method as above, the results are as follows: Table 2 Content ratio of different crystalline tricalcium phosphate synthesized at different calcination reaction temperatures No. Calcination reaction temperature (℃) α-TCP content (%) β-TCP content (%) A 1200 52.07 47.93 B 1300 73.05 26.95 C 1400 100 0

[0043] In order to obtain a portion of α-TCP, the calcium phosphate precursor must be calcined at a certain temperature. This requires calcination above the β→α transition temperature. Nurse et al. determined its phase transition temperature to be 1125 °C, however, in practice, this temperature is considered too low to achieve a certain proportion or complete conversion. Thermal analysis performed in different reports has determined the β→α transition temperature to be 1115±10 °C, 1150 °C, 1157-1195 °C and 1182.4 °C. For the solid phase reaction synthesis of undoped α-TCP, the calcination temperature is usually between 1300-1400 °C.

[0044] The effect of different calcination reaction temperatures on the synthesized TCP crystal phase was studied under the same holding time (4 h). Figure 2It can be seen that the α-TCP synthesized at three calcination reaction temperatures has strong diffraction peaks at 2θ=30.753°, 34.182°, 22.902°, 22.723°, 24.098°, 30.601°, 34.604°, and 31.249°. The eight-strong peak position of β-TCP also shows a diffraction peak. Comparing the α-TCP standard card PDF#09-0348 and the β-TCP standard card PDF#09-0169, the diffraction peak position and intensity are quite consistent, and there are no other impurity peaks. The content was determined and analyzed using Jade 6.5 to obtain the phase composition ratio of the product at different calcination reaction temperatures. As shown in Table 2, with the increase of the calcination reaction temperature, the composition ratio of α-TCP also gradually increased. When the calcination temperature reached 1400℃ and the reaction was 4 h, all pure β-TCP was converted into α-TCP. This reaction parameter can be used as a reference for producing pure α-TCP phase. In addition, no other products are generated except α-TCP and β-TCP at the three calcination reaction temperatures.

[0045] In other embodiments, (2) is calcined at 900°C for 1 hour, and then calcined at 1300°C for 2 hours, 3 hours, and 4 hours, respectively, and then immediately removed from the air and rapidly cooled to room temperature. The synthesized product is ball-milled for 2 hours, dried, and then used. The synthesized product is subjected to phase analysis and compressive strength measurement, and the calcination reaction time with better performance is selected according to the performance of the synthesized biphasic calcium phosphate. Using the same XRD experimental method as above, the results are as follows: Table 3 Content ratio of different crystalline tricalcium phosphate synthesized at different calcination reaction times No. Calcination reaction time (h) α-TCP content (%) β-TCP content (%) A 2 50.96 49.04 B 3 68.36 31.64 C 4 88.95 11.05

[0046] The residence time at the calcination temperature must be sufficient to allow complete conversion of β-TCP to α-TCP, which will depend on the amount of material synthesized. For solid phase reactions, most authors have utilized residence times between 4 and 6 h, with the shortest time reported being 1 h. And longer residence times do not appear to affect the amount of α-TCP phase produced during the synthesis, provided that sufficient time is allowed to complete the formation of α-TCP.

[0047] The influence of different calcination reaction times on the synthesized TCP crystal phase was studied at the same calcination reaction temperature of 1300 ℃. Figure 3It can be seen that the α-TCP and β-TCP synthesized by the three calcination reaction times all have strong diffraction peaks at their eight strong peak positions. Similarly, comparing PDF#09-0348 and PDF#09-0169, the diffraction peak positions and intensities are relatively consistent, and there are no other impurity peaks. According to the content analysis results of Jade 6.5, the longer the calcination reaction time, the higher the α-TCP content, as shown in Table 3. In addition, no other phases are produced during the conversion of β-TCP to α-TCP.

[0048] (4) Ball milling → drying → sieving: Pour the block crystals obtained in (3) into a mortar and grind them into fine particles. Then pour them into a ball mill, add an appropriate amount of ethanol, and ball mill. After the ethanol evaporates, put them in an oven to dry. The obtained powder is sieved through a 325-mesh sieve to obtain a biphasic tricalcium phosphate powder with a median particle size of about 50 μm.

[0049] In some embodiments, the block crystals obtained in step (3) are poured into a mortar and crushed into fine particles. Then, the crystals are poured into a ball mill, and an appropriate amount of ethanol is added, and the ball mill is performed at a speed of 400 rpm / min for 2 h. After the ethanol is naturally evaporated, the crystals are placed in an oven and dried at 70° C. for 4 h. The obtained powder is passed through a 325-mesh sieve to obtain a biphasic calcium phosphate powder with a particle size of about 50 μm.

[0050] In some preferred embodiments, the biphasic tricalcium phosphate is a biphasic tricalcium phosphate with an α-phase / β-phase molar ratio of about 1:1. The compressive strength is shown in Table 4, and the initial and final setting times are shown in Table 5 using biphasic tricalcium phosphate containing α-phase and β-phase with different crystal ratios, the same liquid phase components, and the same mixing method. Table 4 Comparison of compressive strength of different crystalline TCP content ratios (±s, n=5) α-TCP:β-TCP 1:0 3:1 1:1 1:3 0:1 Compressive strength / MPa 37.78±1.21 24.08±2.83 29.58±1.89 8.11±1.05 1.64±0.37 Table 5 Comparison of initial and final setting time of different crystal TCP content ratios (±s, n=3) α-TCP:β-TCP 1:0 3:1 1:1 1:3 0:1 Initial setting / min 3.5 ± 0.5 5 ± 0.5 8 ± 0.5 8 ± 0.5 47 ± 3 Final setting / min 5.5 ± 0.5 11 ± 1 24 ± 1 26 ± 1 96 ± 3

[0051] The data showed that when the content ratio of biphasic calcium phosphate was 1:1, the compressive strength of bone cement was greatly improved [compared with pure β-TCP (1.64±0.37) MPa, (29.58±1.89) MPa, p<0.0001]. Pure α-TCP generates CDHA through hydration reaction, which makes the setting time extremely short. With the addition of β-TCP, the final setting time of BCP bone cement continues to increase. Since β-TCP does not participate in hydration, the amount of α-TCP powder that can undergo hydration reaction is reduced, the actual liquid-solid ratio of the system is increased, and the setting time is extended. In the case of pure β-TCP, its curing principle is to volatilize excess water to achieve a certain strength, so the final setting time is greatly increased.

[0052] In the present invention, the chitosan oligosaccharide is COSM with an average molecular weight of ≤3000 Da.

[0053] In the present invention, the mass concentration of chitosan oligosaccharide in the liquid phase component in water is 0-10wt%; in some embodiments, COSM is added to make it into a liquid phase containing 0 wt%, 1 wt%, 2 wt%, 5 wt%, and 10 wt% COSM.

[0054] In some embodiments, the liquid phase components also include citric acid and disodium hydrogen phosphate.

[0055] In some embodiments, in the liquid phase component, the citric acid is citric acid monohydrate, and its mass concentration in water is 1-3%, preferably 2.09wt%; the mass concentration of disodium hydrogen phosphate in water is 3-6%, preferably 5.0wt%.

[0056] A method for preparing a COSM-loaded biphasic calcium phosphate bone cement, characterized in that the solid phase component and the liquid phase component are uniformly mixed and formed in a mold according to a certain mass ratio.

[0057] In a preferred embodiment, the mass ratio of the solid phase component to the liquid phase component is 1:(0.5-0.6).

[0058] In some embodiments, the solid phase component of BCP bone cement is a biphasic tricalcium phosphate mixed with α-TCP and β-TCP in different ratios.

[0059] In some embodiments, the liquid phase component is prepared by weighing 4.18 g of citric acid monohydrate and 10 g of disodium hydrogen phosphate, adding them into a beaker, adding water to dissolve them, and then adding COSM to make a liquid phase containing 0 wt%, 1 wt%, 2 wt%, 5 wt%, and 10 wt% COSM, and adjusting the volume to 200 mL.

[0060] In some embodiments, a certain amount of solid phase powder is weighed with a weighing balance, and the solidified liquid is weighed according to the mass ratio of the solid phase component to the liquid phase component, that is, the solid-liquid ratio is 1:0.5. The two are placed in a mortar and stirred evenly with a glass rod, and quickly filled into a stainless steel cylindrical hole mold with a diameter of ф6 mm × 12 mm for compaction. A T-shaped punch is used to apply a little pressure to press and form the bone cement particles. After the bone cement particles are formed, they are ejected. During this period, the curing time can be measured, and the prepared bone cement particles are placed in a constant temperature box at 37°C and 100% humidity for curing. After 3 days, the compressive strength, phase analysis and other tests can be performed.

[0061] Example 1 Preparation of solid phase component: According to the method of step (1), the finally obtained calcium carbonate and calcium hydrogen phosphate are mixed evenly and dried, and calcined in a muffle furnace at a heating rate of 5°C / min. After being kept at 900°C for a certain time of 1 hour, the temperature is then raised to 1300°C and calcined for 2 hours. Then, the mixture is immediately taken out and rapidly cooled in air. After cooling to room temperature, the synthetic product is ball-milled for 2 hours, dried and set aside; The liquid phase components were prepared by weighing 4.18 g of citric acid monohydrate and 10 g of sodium hydrogen phosphate, adding them into a beaker, adding water and stirring to dissolve, and then adding COSM to form a liquid phase containing 1 wt% COSM, which was fixed to 200 mL. In some embodiments, a certain amount of solid phase powder is weighed with a weighing balance, and the solidified liquid is weighed according to the mass ratio of the solid phase component to the liquid phase component, that is, the solid-liquid ratio is 1:0.5. The two are placed in a mortar and stirred evenly with a glass rod, and quickly filled into a stainless steel cylindrical hole mold with a diameter of ф6 mm × 12 mm for compaction. A T-shaped punch is used to apply a little pressure to press and form the bone cement particles. After the bone cement particles are formed, they are ejected. During this period, the curing time can be measured, and the prepared bone cement particles are placed in a constant temperature box at 37°C and 100% humidity for curing. After 3 days, the compressive strength, phase analysis and other tests can be performed.

[0062] Example 2 The steps are the same as those of Example 1, except that the concentration of COSM in the liquid phase component is 2 wt %.

[0063] Example 3 The steps are the same as those of Example 1, except that the concentration of COSM in the liquid phase component is 5 wt %.

[0064] Example 4 The steps are the same as those of Example 1, except that the concentration of COSM in the liquid phase component is 10 wt %.

[0065] Comparative Example 1 The steps are the same as those of Example 1, except that the concentration of COSM in the liquid phase component is 0 wt %.

[0066] Performance testing and characterization 1. Field emission scanning electron microscopy (SEM) observation of BCP bone cement A Zeiss Sigma300 field-emission scanning electron microscope (Field-emission Scanning Electron Microscope, Germany) was used to observe the microscopic morphology of biphasic calcium phosphate powder and the microscopic results of the samples after curing calcium phosphate bone cement. Since BCP powder and cured bone cement samples are not conductive, the sample surface was sprayed with gold using an ion sputtering instrument before observation, and then the sample was glued on a conductive glue to observe the powder size and CPC morphology.

[0067] Figure 4 The microscopic morphology of biphasic calcium phosphate cement (α-TCP / β-TCP molar ratio is 1) loaded with different contents of COSM. Figure 4 A shows that the CPC particles without COSM are covered with a layer of hydrated CDHA phase on the surface. The presence of β-TCP forms irregular pores, and the CDHA covering the surface further hinders the hydration of α-TCP, retaining a good porosity. With the addition of COSM, the surface morphology of CPC hydration products presents a flaky structure ( Figure 4 BE), and further increases with the increase of COSM content, its surface pores are blocked and reduced, from which it can be speculated that its compressive strength is improved. The reason for this change may be that the addition of COSM delays the curing process of CPC, allowing it to fully hydrate into CDHA.

[0068] 2. Mercury Intrusion Porosimetry (MIP) Analysis of BCP Bone Cement Mercury intrusion porosimetry (MIP), also known as mercury porosimetry, is the main method for determining mesopores, macropores, and pore size distribution. Three BCP bone cement samples were randomly selected and their porosity, pore size, and pore distribution were tested using the American McMerritt AutoPore Ⅳ 9520 mercury intrusion instrument.

[0069] Figure 5The relevant analysis results of MIP detection of biphasic calcium phosphate bone cement with 5 wt% COSM after hydration and curing for 3 days. The porosity calculated by Washburn equation was 50.18%, the average pore size 4V / A was 49.16 nm, the total pore volume was 0.3761 mL / g, and the total pore area was 30.597 m2 / g. Compared with biphasic calcium phosphate bone cement without COSM, its porosity was slightly reduced, the total pore volume did not change much, but the average pore size was reduced by 1 / 3. Combined with the results of scanning electron microscopy, after adding COSM, the hydration process was prolonged, CDHA increased, and a certain covering effect was produced on the bone cement. From the perspective of total pore volume and total pore area, COSM-BCP lacks large pores and through pores. Compared with blank BCP, the process needs to be optimized to improve angiogenesis and degradation performance.

[0070] Compared with biphasic calcium phosphate cement without COSM, Figure 6 The results of MIP analysis of biphasic calcium phosphate cement after hydration and curing for 3 days are shown in Figure 2. The porosity of biphasic calcium phosphate cement was calculated to be 52.09% using the Washburn equation, which meets the requirements of bone tissue engineering. In addition, the average pore size 4V / A is 76.59 nm, the total pore volume is 0.3938 mL / g, and the total pore area is 20.568 m2 / g.

[0071] 3. Analysis of the physical and chemical properties of BCP bone cement 3.1 Determination of curing time The curing time was determined by the Vicat needle method, and the initial setting time and final setting time of bone cement were used for determination. The curing time was based on the final setting time. Weigh an appropriate amount of BCP bone cement powder, mix it at the same solid-liquid ratio (1:0.5), and start timing. Pour it into the mold, contact the Vicat needle with the cement surface, tighten the screw, and relax it after 1~2s. The Vicat needle sinks vertically into the cement slurry, and the sinking distance is recorded. Repeat every 0.5 min. When the Vicat needle cannot penetrate the cement slurry, it is initial setting. According to the above method, replace the initial setting needle with the final setting needle, contact the needle with the cement surface, tighten the screw, and relax it after 1~2s. The Vicat needle sinks vertically into the cement slurry, and the sinking distance is recorded. Repeat every 0.5 min. When the Vicat needle cannot leave a clear mark, it is final setting.

[0072] Table 6 and Figure 7The figure shows the comparison of the curing time of BCP loaded with different contents of COSM. When the COSM content is 1 wt%, the initial and final setting times are slightly lower than those of BCP without COSM. This may be because adding an appropriate amount of COSM can accelerate the dissolution rate of α-TCP, allowing it to quickly form a stable structure and shorten the curing time. However, as the content of COSM increases, the curing time of COSM-BCP also increases in a gradient manner with the COSM content. Excessive COSM slows down the process of liquid diffusion, prolongs the formation time of the CDHA shell, and prevents it from forming a stable structure, thereby prolonging the curing time.

[0073] Table 6 Comparison of initial and final setting time of bone cement loaded with different contents of COSM (±s, n=3) COSM contentBlank 0% 1wt% 2wt% 5wt% 10wt% Initial setting / min 8±0.5 6.9±0.3 9.5±0.4 11±0.5 22.5±0.5 Final setting / min 24±1 21.5±0.5 24±1 26.5±1 40.9±0.7

[0074] 3.2 Compressive strength determination The BCP powder and curing liquid of different proportions were mixed evenly to make cylindrical curing samples (ф6 mm×12 mm). The samples were placed in a constant temperature and humidity chamber at 37 °C and relative humidity greater than 95% for 3 days, and then the samples were taken out and dried. The upper and lower surfaces of the cylindrical samples were polished flat with sandpaper, and the mechanical test of the cured samples was carried out using a universal mechanical testing machine, and the test loading rate was 0.5 mm / min.

[0075] Table 7 and Figure 8 The figure shows the compressive strength comparison of BCP loaded with different contents of COSM. When the COSM content is 1 wt% and 2 wt%, there is no significant change in the compressive strength compared with BCP without COSM; when the COSM content is 5 wt% and 10 wt%, its compressive strength is significantly higher than that of other groups of BCP, and the compressive strength of BCP with COSM is higher. From the analysis results, it can be seen that the addition of COSM can reduce the pore size and porosity, but it leads to the enhancement of the compressive strength of COSM-BCP. In addition, from the analysis results, it can be seen that the increase in COSM content is positively correlated with the curing time of BCP, which is conducive to enhancing the degree of hydration and the precipitation of CDHA crystals.

[0076] Table 7 Comparison of compressive strength of bone cement loaded with different contents of COSM (±s, n=5) COSM contentBlank 0% 1 wt% 2 wt% 5 wt% 10 wt% Compressive strength / MPa 23.21±1.21 23.51±1.74 22.01±1.03 27.98±2.66 31.27±2.99

[0077] 3.3 Determination of anti-collapse performance Pour the slurry obtained by mixing BCP with 0% chitosan oligosaccharide solidifying liquid into the mold. After the bone cement solidifies, immediately push the particles out with a T-shaped column, weigh the particles and record them as M0, put them in a beaker, and then pour PBS so that the volume to sample mass ratio is 30 mL / g. Oscillate in an oscillating incubator at 37 °C and 120 rpm / min. Take out at 1 min, 3 min, 7 min, 11 min, and 15 min, absorb the liquid on the surface of the sample with filter paper, weigh it, and record the mass as M1. Calculate the weight percentage of the uncollapsed solid body to the initial total solid body, and record it as the anti-collapse rate. Each group is parallel 3 times and the average value is taken. The anti-collapse rate calculation formula is as follows: 00% Where, M1 is the mass of bone cement particles after oscillation. M0 – the initial mass of bone cement particles.

[0078] The anti-disintegration property of calcium phosphate cement means that during the solidification process, CPC can still maintain its complete shape in the solution and will not be disintegrated by liquid erosion. The anti-disintegration property of calcium phosphate cement is also one of the important parameters of the performance of bone surgery. In clinical applications, when CPC paste comes into contact with biological fluids or blood at the surgical site, it is easy to disintegrate due to its weak cohesion. Solid particles separated from CPC may enter the bloodstream and cause severe inflammatory reactions, pulmonary embolism and cardiovascular deterioration during vertebroplasty or kyphoplasty.

[0079] Fig. 9 and Fig.10 These are the qualitative and quantitative analysis results of the anti-collapse effect of biphasic calcium phosphate. After the bone cement was shaken in PBS, a small amount of powder collapsed, but it still maintained its complete shape. After the oscillation time reached 15 min, the anti-collapse rate of CPC reached 86.39%±0.32%. The results show that the matrix of biphasic calcium phosphate bone cement can still maintain 85% of its mass during the curing process, and its anti-collapse performance is good.

[0080] 3.4 In vitro degradation experiment The in vitro degradation rate was measured by soaking the sample with 0% chitosan oligosaccharide in PBS buffer solution (pH=7.4). The CPC cured for 3 days was dried and weighed for the initial weight, soaked at a ratio of 0.1 g / mL, and then placed in a constant temperature shaker at 37 °C and a speed of 60 rpm / min. After 1, 3, 7, 14, 21, 28, and 37 days, the samples were taken out, rinsed with deionized water, dried and weighed. The in vitro degradation rate was calculated as the percentage of the weight after drying to the initial weight. There were 3 independent samples in each group, and the results were averaged.

[0081] Appropriate degradation rate is of great significance for bone repair materials. Generally speaking, placing a bioactive scaffold with an appropriate degradation rate in the body can provide space for matrix deposition and bone ingrowth until osteogenesis is completed. Fig.11 As shown in the figure. In our study, the weight of bone cement particles increased slightly after immersion in PBS buffer for 1 day, which may be due to the fact that there is still unhydrated α-TCP in the particles, and the CDHA produced after hydration improves its quality. As the immersion time increases, the mass retention rate of bone cement gradually decreases. After 37 days, its mass retention rate is 95.54 ± 0.38%. And throughout the process, all samples maintained their original shape, proving that the samples can maintain their strength during the degradation process and meet the mechanical support requirements of bone regeneration. Since the in vitro degradation experiment only involves the physical and chemical dissolution process of the material itself, the β-TCP component will also degrade under the action of proteins and cells. Therefore, the in vivo degradation of BCP bone cement needs further verification. In addition, crystallinity, specific surface area, porosity, etc. are also physical factors that affect the degradation rate.

[0082] IV. In vitro drug release experiment First, the COSM analysis method was established: The principle of the DNS method is that 3, 5-dinitrosalicylic acid is reduced to a brown-red amino compound, 3-amino-5-nitrosalicylic acid, after being heated with reducing sugars from polysaccharide hydrolysis under neutral or alkaline conditions. Within a certain range, the amount of reducing sugar is proportional to the color of the reaction solution. However, the literature on the DNS determination wavelength includes 540nm, 520 nm, and 490 nm, which leads to different standard curves and linear ranges, and the accuracy and precision will also be affected. Here we construct a methodological system to investigate and verify the DNS method for COSM determination. Through the detection wavelength, linearity, precision, stability, and sample recovery experiments, the experimental results show that the DNS method is accurate at a detection wavelength of 540nm.

[0083] The above-established DNS method was used to detect the drug concentration of COSM released from the examples and comparative samples in vitro. The drug release sample was a cylinder with a diameter of 6 mm and a height of 12 mm prepared above, and PBS (pH=7.4) was added as a drug release medium at a ratio of 10 mL / g. The solution was taken and stored for testing at selected time points (3, 6, 12, 18, 24, 48, 72, 96, 120, 144, 168 h), and an equal amount of PBS solution was added to the original drug release system. After the obtained drug solution was treated with the DNS method, it was tested according to the established equation.

[0084] Fig.12 The in vitro drug release curve of BCP bone cement loaded with different contents of COSM. COSM with different contents can be stably and continuously released in the drug-loaded system. BCP with 10 wt% COSM showed an initial burst release of COSM, followed by a slow release after 12 h. As the COSM content decreased, the release of COSM-BCP in each group became more sustained and slow. The release of the biphasic calcium phosphate bone cement system may be related to its degradation properties. COSM attached to the surface and pores of BCP will be released into the solution and enter a burst release state. As BCP disintegrates and degrades, the embedded COSM will gradually be released and enter a long-term sustained release state.

[0085] 5. In vitro biocompatibility evaluation of COSM-BCP bone cement Preparatory experiments Preparation of cell experiment solution: Preparation of α-MEM medium containing 10% FBS: Take FBS and α-MEM basal medium, prepare them in a ratio of 1:9 and store them in a 50 mL centrifuge tube. Add double antibody at a content of 1% before use and mix them evenly; Preparation of DMEM medium containing 10% FBS: Except for DMEM basal medium, perform the same operation as above; Preparation of freezing solution: Prepare it in a ratio of FBS: DMSO = 9:1, store it in a refrigerator at 4 ℃ away from light, and use it immediately after preparation.

[0086] Preparation of extract: COSM-BCP bone cement particles with different concentrations (BCP containing 0 wt%, 1 wt%, 2 wt%, 5 wt%, and 10 wt% COSM) were sterilized by ultraviolet light, then extracted with 10 mL / g complete culture medium for 2 d. The bone cement particles were filtered out, sterilized using a 0.22 μm microporous filter membrane, and stored in a -4 ℃ refrigerator.

[0087] 5.1 Cell culture 5.1.1 Cell recovery and culture (1) Take the cells out of the liquid nitrogen tank and quickly place them in a 37°C constant temperature water bath to shake and thaw until there are no ice crystals in the cells in the cryopreservation tube; (2) Transfer the thawed cells to a 15 mL centrifuge tube, add at least 2 volumes of complete culture medium, blow evenly, then centrifuge at 900 rpm / min for 4 min and discard the supernatant; (3) Add complete culture medium to the centrifuged tube and gently pipette to resuspend it; (4) Transfer the above cells to a culture bottle pre-filled with complete culture medium, make a cross-section to evenly distribute the cells on the bottom of the bottle, and place the cells in a cell incubator for culture; (5) After two days of growth in the cell culture flask, observe the cell density and morphology, gently aspirate the old culture medium, rinse the cells twice with rewarmed PBS buffer, add an appropriate amount of new culture medium, and return the cells to the incubator for culture. The culture medium should be changed every two days.

[0088] 5.1.2 Cell passaging and cryopreservation When the cell confluence reaches 85-90%, the cells can be passaged: aspirate the culture medium in the culture bottle, add PBS to rinse 1-2 times, and wash away the floating cells; after aspirating PBS, add an appropriate amount of trypsin, and place in the incubator for digestion for 1-2 minutes; then immediately add at least 2 times the volume of trypsin culture medium to terminate digestion, repeatedly blow and rinse the cell bottle wall; transfer to a 15 mL centrifuge tube, centrifuge at 900 rpm / min for 4 min, and discard the supernatant; add culture medium, blow and suspend, and divide into culture bottles at a ratio of 1:2 or 1:3, and place in the incubator for continued culture.

[0089] When the cell experiment is completed and the cells grow to 85-90% confluence, the cells can be frozen: according to the cell culture steps, rinse the cells with PBS, digest the cells and centrifuge them, discard the supernatant, add 1 mL of freezing solution (DMSO: FBS = 1:9), pipette to mix, and transfer to cryopreservation tubes; mark the cell type, generation and freezing date on the cryopreservation tubes and keep records; place the cell cryopreservation tubes in a gradient freezing box, freeze them in a -80℃ refrigerator overnight, and finally transfer them to a liquid nitrogen tank for long-term storage.

[0090] 5.2 In vitro cell proliferation assay MC3T3-E1s and HUVECs in the logarithmic growth phase were carefully blown and centrifuged, and complete medium was added and blown evenly to adjust the cell density to 8×104 cells / mL. Then the cell suspension was aspirated into a 96-well plate, 100 μL per well, and placed in an incubator for 6 h. The well plate was taken out, the cell culture medium in each well was aspirated and discarded, and new complete culture medium was added to set as the blank control group. Different concentrations of COSM-BCP bone cement particle extracts were set as the experimental group. Each group had 6 replicates, and the cells were cultured for 1 d and 3 d respectively. The cell proliferation of each group was tested using the CCK-8 kit. The culture medium of each group was aspirated and discarded, and 100 μL of complete culture medium containing 10% CCK-8 solution was added to each well. The wells were placed in an incubator for 2 h, and the 96-well plate was taken out to terminate the culture. The absorbance of each well in each group was measured at a wavelength of 450 nm on the microplate reader, and the cell survival rate of each group was calculated according to the formula, and the cell proliferation of each group was compared.

[0091]

[0092] Where: As: absorbance of the experimental well (culture medium containing cells, CCK-8, and samples to be tested) Ac: Absorbance of control well (culture medium containing cells, CCK-8, no sample to be tested) Ab: absorbance of blank group (culture medium of the sample to be tested without cells, CCK-8)

[0093] 5.3 In vitro cell scratch assay First, mark the 6-well plate, and use a marker and ruler to draw horizontal lines on the bottom of the 6-well plate, and draw a line every 0.5-1 cm, crossing the hole horizontally. HUVECs were inoculated into the 6-well plate at a concentration of 2.5×105 / mL, and 2 mL of cell suspension was added to each well, and then placed in an incubator for 6 h. When HUVECs crawled all over the bottom of the dish, a 200 μL enzyme-free pipette tip was used to make a vertical scratch on the bottom of the well, so that the scratch intersected with the marked line, and the original culture medium was discarded, and then rinsed with PBS twice. Different concentrations of COSM-BCP extracts (BCP containing 0 wt%, 1 wt%, 2 wt%, 5 wt%, and 10 wt% COSM) were set as experimental groups, and blank culture solutions were set as blank control groups (all without fetal bovine serum), with 3 replicates in each group. Observe and take pictures under an inverted microscope at 12 h and 24 h. Image J software was used to calculate the migration area and analyze the migration of cells.

[0094] 5.4 In vitro tubule formation assay HUVECs were starved: HUVEC cells with a confluency of 70-80% were used, and the complete culture medium was replaced with DMEM culture medium containing 0.2% FBS as the blank control group, and BCP extract containing 0 wt%, 1 wt%, 2 wt%, 5 wt%, and 10 wt% COSM was used as the experimental group, and cultured for 24 h. The matrix gel was placed on ice and melted at 4 °C, and the matrix gel required for each well was dispensed using a pre-cooled 2 mL centrifuge tube and a pipette tip. A 48-well plate was placed on ice, and 100 μL of matrix gel was added to each well of the 48-well plate according to 3 replicates per group, and then placed in an incubator for 30 min to solidify the matrix gel. HUVEC cells in each group were digested, resuspended and counted in DMEM containing 10% FBS, and 200 μL of cell suspension with a cell concentration of 4×105 / mL was added to each well of the 48-well plate. The 48-well plate was placed in an incubator for 4 h, then taken out and observed under an inverted microscope for tube formation and three fields of view were randomly selected for image acquisition. Image J software was used to measure and analyze the number of meshes, number of connection nodes, number of branches, and total length of branches in each tubule structure to analyze the in vitro tubule formation.

[0095] 5.5 In vitro RT-PCR experiments 5.5.1 Primer design The primer sequences of human ANG1, bFGF, CXCR4, PDGFRB, VEGFA, VEGFB and GAPDH genes were verified by consulting the literature and using Pubmed search, and the primers were synthesized by Shanghai Sangon Biotechnology Co., Ltd. The primer sequences are shown in Table 8: Table 8 RT-PCR primer sequences Gene name Primer sequence (5'→3') GAPDH F: GAAAGCCTGCCGGTGACTAA R:GCCCAATACGACCAAATCAGAG ANG1 F:CAGTGGCTGCAAAAACTTGAGA R:AGTCTGAGAGAGGAGGCTGG bFGF F:GCGACCCTCACATCAAGCTA R:AGCCAGGTAACGGTTAGCAC CXCR4 F:GGGCAGAGGAGTTAGCCAAG R: GGGCTAAGGGCACAAGAGAA PDGFRB F:CCATCAGCAGCAAGGCGA R: AGCAGGTCAGAACGAAGGTG VEGFA F:ACAAATGTGAATGCAGACCAAA R:ACCAACGTACACGCTCCAG VEGFB F: CAAGTCCGGATGCAGATCCT R:TCTGCATTCACACTGGCTGT

[0096] 5.5.2 Extraction of total RNA from cells (1) HUVECs were cultured in vitro. 50,000 cells were seeded per well in a 6-well plate and placed in an incubator for 6 h. (2) Grouping and drug administration are the same as in 4.3.3, and then placed in an incubator for 2 days; (3) Take out the 6-well plate containing cells and place it on an ice box. Gently wash it twice with PBS. (4) Add 1 mL RNAiso plus lysis buffer to each well and lyse for 3 min, pipetting repeatedly; (5) Transfer to an enzyme-free EP tube, add 200 μL CHCL3, shake gently, and let stand for 2 min; (6) After sufficient lysis, centrifuge at 12,000 rpm for 15 min at 4 °C; (7) Place 400 μL of the supernatant in a new 1.5 mL EP tube without enzyme, add 500 μL of isopropanol, invert and mix, let stand at room temperature for 10 min, and centrifuge at 4 °C, 12,000 rpm for 15 min. (8) Pour off the isopropanol, add 500 μL of 70% ethanol, gently invert to wash the tube wall, centrifuge at 7500 rpm at 4 °C for 5 min, carefully pour off the supernatant, and repeat this step once; (9) Discard the supernatant, blow for 5-10 min in a clean bench, add 30 μL of DEPC water to dissolve the precipitate, and measure the RNA concentration using NanoDrop. The ratio of the OD value at 260 nm to the OD value at 280 nm is used to determine the purity of the RNA. A ratio in the range of 1.8-2.0 indicates that the RNA purity is acceptable. Dilute the total RNA solution to a concentration of 1000 ng / mL, aliquot, and store in a -80 ℃ refrigerator.

[0097] 5.5.3 Removal of genomic DNA and reverse transcription of RNA to synthesize cDNA (1) Removal of genomic DNA (10 μL reaction system): Add the reagents in the table to 200 μL enzyme-free EP tubes in sequence, shake to mix, centrifuge at high speed for 30 s, place in a gradient PCR amplification instrument for reaction (42 ℃, 2 min), and store in an ice box immediately after the reaction is completed.

[0098] Reagent volume / μL 5×DNA Eraser Buffer 2.0 gDNA Eraser 1.0 RNase Free H2O 6.0 Total RNA 1.0

[0099] (2) Reverse transcription reaction (20 μL reaction system): Add the reagents in the table to the centrifuge tube in (1) in sequence, oscillate to mix, centrifuge at high speed for 30 s, and place in a gradient PCR amplification instrument for reaction (37 ℃, 15 min→85 ℃, 5 s). After reverse transcription is completed, add 72 μL of DEPC water to 20 μL of cDNA system to dilute it to a concentration of 0.2 μmol, and store it in a -80 ℃ refrigerator.

[0100] Reagent volume / μL The above system 10.0 PrimeScript RT Enzyme mix 1 1.0 RT Rrimer Mix 1.0 5×PrimeScript buffer 2 4.0 RNase Free H2O 4.0

[0101] 5.5.4 RT-PCR reaction Add the reagents in the table to the Roche 384-well PCR plate in sequence, stick the sealing film to the PCR plate, centrifuge for 2 minutes, and react in the Roche PCR instrument. The reaction procedure is: pre-denaturation (95 ℃, 30 s) → denaturation and annealing (95 ℃, 5 s; 60 ℃, 30 s / cycle) (40 cycles). After the reaction is completed, GAPDH is used as the internal reference gene, and the 2-△△Ct method is used to analyze the gene expression between groups and calculate the relative expression of the detected genes.

[0102] Reagent volume / μL Upstream primer (10 μM) 0.6 Downstream primer (10 μM) 0.6 TB Green Premix Ex TaqTM Ⅱ 5.0 cDNA Template 2.0 DEPC water 1.8

[0103] 5.6 Data Statistical Analysis The data obtained in this experiment were analyzed and processed using SPSS26.0 and GraphPad Prism9.0 software, and the One-Way ANOVA method was used to compare and analyze the significant differences among the groups. p < 0.05 indicated statistical significance. The final results of the experiment were expressed as mean ± SD.

[0104] 5.7 Experimental Results Analysis 5.7.1 Analysis of the proliferation of MC3T3-E1s and HUVECs by COSM-BCP extract Cell proliferation and toxicity testing is a type of biocompatibility testing that can reflect the toxicity or growth of drugs and materials in biological environments to a certain extent, especially in osteogenesis and angiogenesis, which play an important role in bone development and fracture healing.

[0105] Therefore, mouse osteoblasts MC3T3-E1 and human umbilical vein endothelial cells HUVEC were used to evaluate the cytotoxicity of BCP bone cement particle extracts with different concentrations of COSM, with normal culture medium as the control group. Fig.13 Figure 3 Cell morphology and number of mouse osteoblasts in different COSM-BCP bone cement particle extracts. It can be observed that the cells in each group grew adherently after 1 day and 3 days and were in good condition. Most of the cells were long spindle-shaped or polygonal with plump cell bodies. Fig.14 The data in the middle show that after 1 day of culture, the cell proliferation rate of all materials at each concentration was greater than 80%. According to the ISO 10993-5-2009 standard, the extracts of each concentration within 1 day had no obvious toxicity to MC3T3-E1. After 3 days of culture, compared with the normal control group, the cell proliferation of each group was further increased. Except for the 10 wt% COSM-BCP particle extract, the differences in other groups were statistically significant (p < 0.05). This shows that the bone cement extract and the COSM contained in it play a positive role in cell compatibility to a certain extent, but too high a concentration of COSM will reduce cell proliferation.

[0106] Similarly, after being cultured in different COSM-BCP bone cement particle extracts for 1 and 3 days, HUVECs were in good condition and were polygonal, fusiform, or oval. Moreover, the number of cells increased significantly after 3 days of culture, occupying the entire visual field ( Fig.15 ).Depend on Fig.16The data showed that after 1 day of culture, the cell proliferation rate of all materials at each concentration was greater than 80%, and the extracts at different concentrations were all first-level cytotoxic to HUVECs, with low cytotoxicity. After 1 day of culture, 0 wt% COSM-BCP particles were statistically significant compared with the Control group; after 3 days of culture, the cell proliferation of each group increased further, and except for the 10 wt% COSM-BCP particle extract, the differences in other groups were statistically significant (p < 0.05). It can be seen that the extract of COSM-BCP and COSM have no obvious toxicity to HUVECs and have a certain promoting effect.

[0107] 5.7.2 Analysis of the effect of COSM-BCP extract on HUVECs migration ability Cell migration is one of the basic functions of normal cells and a very important physiological process for normal growth and development in bone defect healing and wound healing. The scratch test was used to evaluate the migration of HUVECs from the scratch edge to the blank area, and the migration ability of each group of cells was compared. The experimental results showed that with the increase of culture time, the scratch area of ​​each group of cells decreased ( Fig.17 Compared with the Control group, the COSM-BCP particle extract had no inhibitory effect on the healing rate of HUVECs at 12 h and 24 h ( Fig.18 ). Compared with the control group, the differences among the groups were statistically significant (p < 0.05). In particular, the scratch area of ​​the skin treated with 10 wt% COSM-BCP particle extract was significantly reduced after 24 h, and the healing rate was close to 80% ( Fig.18 ).

[0108] 5.7.3 Analysis of the effect of COSM-BCP extract on the angiogenic ability of HUVECs There is evidence that blood vessels, especially their endothelial cells (EC), control the growth, balance and regeneration of bones. Kusumbe and colleagues have shown that bone blood vessels contain endothelial cells that are specialized to support bone maturation and regeneration. Angiogenesis is a key process in tissue repair and regeneration, and ECs build tubular structures during cell proliferation and migration to the tissue defect area.

[0109] Tubule formation assay Fig.19 and Fig. 20The results showed that both the BCP extract containing COSM and the normal group could induce HUVECs to arrange into tubule-like structures. There was no significant difference between the two groups before the BCP containing 5 wt% COSM concentration, and the results were not statistically significant compared with the control group. In the 10 wt% COSM-BCP extract culture medium, the number of tubes formed, the total length and the number of nodes were significantly different from those in the control group (p < 0.05). It was preliminarily proved that COSM-BCP extract could promote the tube formation of HUVECs.

[0110] 5.7.4 Analysis of the expression of angiogenesis-related genes in HUVECs by COSM-BCP extract To investigate the angiogenic mechanism of COSM-BCP particles on HUVECs, the expression of key regulators of vascular growth was measured. RT-PCR analysis of cell lysates treated with COSM-BCP particles in cultured HUVECs showed that it increased the mRNA levels of ( Fig.21 ), the gene expression effect of HUVECs treated with COSM-BCP particles at a concentration of 5 wt% was the most significant difference (p < 0.05). The results showed that COSM-BCP promoted the upregulation of a series of cytokine parameters and promoted angiogenesis, which was consistent with the experimental results of migration and tubule formation.

Claims

1. Loaded with COSM biphasic calcium phosphate cement, It is characterized in that Solid phase composition: biphasic tricalcium phosphate containing α phase and β phase; Liquid phase component: aqueous solution containing chitosan oligosaccharide.

2. The COSM biphasic calcium phosphate bone cement according to claim 1, It is characterized in that In the solid phase component, the molar ratio of α-phase to β-phase tricalcium phosphate is about 1:

1.

3. The COSM biphasic calcium phosphate bone cement according to claim 2, It is characterized in that The preparation method of the biphasic tricalcium phosphate is as follows: CaCO3 and CaHPO4 are mixed in proportion, first calcined at 900°C for a certain time, then heated to 1300°C for calcination, and rapidly cooled to room temperature to obtain a biphasic tricalcium phosphate with an α phase / β phase molar ratio of about 1:

1.

4. The COSM biphasic calcium phosphate bone cement according to claim 1, It is characterized in that The chitosan oligosaccharide is COSM with an average molecular weight of ≤3000 Da.

5. The COSM biphasic calcium phosphate bone cement according to claim 1, It is characterized in that In the liquid phase component, the mass concentration of chitosan oligosaccharide in water is 1-10wt%.

6. The COSM biphasic calcium phosphate bone cement according to claim 5, It is characterized in that In the liquid phase component, the mass concentration of chitosan oligosaccharide in water is 1wt%, 2wt%, 5wt% and 10wt%.

7. The COSM biphasic calcium phosphate bone cement according to claim 1, It is characterized in that The liquid phase components also include citric acid and disodium hydrogen phosphate.

8. The COSM biphasic calcium phosphate bone cement according to claim 1, It is characterized in that In the liquid phase component, the citric acid is citric acid monohydrate, and the mass concentration of the citric acid in water is 2.09wt%; the mass concentration of the disodium hydrogen phosphate in water is 5wt%.

9. The COSM biphasic calcium phosphate bone cement according to claim 1, It is characterized in that The mass ratio of the solid phase component to the liquid phase component is 1:(0.5~0.6).

10. The method for preparing the COSM-loaded biphasic calcium phosphate bone cement according to any one of claims 1 to 9, It is characterized in that The solid phase component and the liquid phase component are uniformly mixed in a mold and molded.